Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.
2.

Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML).

Cianfriglia M.

Ann Ist Super Sanita. 2013;49(2):190-208. doi: DOI: 10.4415/ANN_13_02_11. Review.

3.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R.

Clin Cancer Res. 2001 Jun;7(6):1490-6. Erratum in: Clin Cancer Res 2002 Jan;8(1):300.

4.

Antibody-drug conjugate technology development for hematologic disorders.

Bander NH, Czuczman MS, Younes A.

Clin Adv Hematol Oncol. 2012 Aug;10(8 Suppl 10):1-16.

PMID:
23072775
5.

Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Takeshita A.

Int J Hematol. 2013 Jun;97(6):703-16. doi: 10.1007/s12185-013-1365-1. Epub 2013 May 26. Review.

PMID:
23709007
6.

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.

Ricart AD.

Clin Cancer Res. 2011 Oct 15;17(20):6417-27. doi: 10.1158/1078-0432.CCR-11-0486. Review.

7.

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.

Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, Bernstein ID.

Blood. 2001 Aug 15;98(4):988-94.

8.
9.
10.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association.

Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5.

PMID:
22482940
11.

Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?

O'Hear C, Rubnitz JE.

Expert Rev Hematol. 2014 Aug;7(4):427-9. doi: 10.1586/17474086.2014.924849. Epub 2014 May 29.

PMID:
24871925
12.

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.

Duong HK, Sekeres MA.

Clin Interv Aging. 2009;4:197-205. Epub 2009 May 14. Review.

13.
14.

Antibody-drug conjugates: present and future.

Beck A, Reichert JM.

MAbs. 2014 Jan-Feb;6(1):15-7. doi: 10.4161/mabs.27436.

PMID:
24423577
15.

Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.

Parigger J, Zwaan CM, Reinhardt D, Kaspers GJ.

Expert Rev Anticancer Ther. 2016;16(2):137-46. doi: 10.1586/14737140.2016.1129903. Epub 2016 Jan 14. Review.

PMID:
26646091
17.

What happened to anti-CD33 therapy for acute myeloid leukemia?

Jurcic JG.

Curr Hematol Malig Rep. 2012 Mar;7(1):65-73. doi: 10.1007/s11899-011-0103-0. Review.

PMID:
22109628
18.

[Gemtuzumab ozogamicin for treatment of acute myeloid leukemia].

Brotelle T, Lemal R, Moluçon-Chabrot C, Bay JO, Delaunay J, Guièze R.

Bull Cancer. 2014 Feb;101(2):211-8. doi: 10.1684/bdc.2014.1886. Review. French.

PMID:
24557850
19.

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.

Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M, Yamakawa Y, Tanimoto M, Kobayashi M, Ohnishi K, Ohno R.

Leukemia. 2002 May;16(5):813-9.

20.

Are immunoconjugates approaching "standard of care" in AML?

Estey E.

Best Pract Res Clin Haematol. 2013 Sep;26(3):261-8. doi: 10.1016/j.beha.2013.10.006. Epub 2013 Oct 16. Review.

PMID:
24309528
Items per page

Supplemental Content

Write to the Help Desk